PepGen Inc. — Form 8-K
Filed November 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
PepGen reported positive Phase 2 topline data from the 10 mg/kg dose cohort of FREEDOM2-DM1 evaluating PGN-EDODM1 in myotonic dystrophy type 1 (DM1). Key results: mean splicing correction of 46.5% (highest reported in a multiple-dose study), with 5 of 6 patients showing >20% improvement and 4 of 6 exceeding 50% correction; functional improvements across video Hand Opening Time (52.7% improvement, 3.9 seconds), hand grip strength (16.2% improvement), Timed Up and Go (8.5% improvement), and 10-Meter Walk/Run Test (6.8% improvement); favorable safety profile with no serious/severe adverse events, no dose-limiting toxicities, or discontinuations. The 12.5 mg/kg cohort is fully enrolled with results expected H1 2027. Company has $104.8M cash (sufficient runway into 2028) with 69.3M shares outstanding as of September 30, 2026. Q3 2026 net loss was $19.4M ($0.28 per share).
Why this rating
Clinical breakthrough in rare disease addressing unmet need; significant relative to ~$17M market cap. Partial FDA clinical hold remains material risk; regulatory path still uncertain. Positive functional data supports Phase 3 pathway.
Tradability signal
SHORT
conviction 19/100 · expected -0.38% over 4 hrs
SHORT (fade the pop): stock already ran +24.8% on this news, and positive calls in this cell have historically given the pop back (-0.40% over 4 hrs, n=417). Reversion play, lower conviction by design. Exit plan: HARD stop 8% against entry — 1.4× this stock's measured hourly volatility, fixed, not trailing (trails test terribly on these names) — time exit 4 hrs. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $4.96 ▼ 13.87% | at our read · unknown $5.76 | +10 min · unknown $6.26 ▲ 8.75% | +30 min · unknown $5.77 ▲ 0.17% | +1 hr · unknown $6.00 ▲ 4.25% | +4 hrs · unknown $5.03 ▼ 12.69% |
The stock had already moved +16.11% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.